Preclinical Assets Market Analysis Covering Drivers and Future Outlook

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Growth In Market Value Is Expected For The Preclinical Assets Market Between 2026 And 2030?

The preclinical assets market has experienced robust growth in recent years. It is projected to expand from $6.38 billion in 2025 to $7.01 billion in 2026, registering a compound annual growth rate (CAGR) of 9.8%. This historical expansion can be attributed to several factors, including increasing pharmaceutical R&D investments, the expansion of early-stage drug discovery programs, a growing reliance on animal-based testing, the rising demand for safety data generation, and the increasing outsourcing of preclinical studies.

The preclinical assets market is projected to experience substantial expansion over the coming years, reaching $10.2 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.8%. This anticipated growth during the forecast period is fueled by several factors, including the greater uptake of human-relevant preclinical models, a heightened need for faster drug development timelines, the broadening of personalized medicine pipelines, increased incorporation of AI in preclinical research, and a strengthened regulatory focus on data reliability. Key trends emerging during this forecast period encompass the wider utilization of sophisticated preclinical models, an uptick in the adoption of patient-derived xenograft and organoid models, an increasing requirement for comprehensive preclinical services, the broadening scope of safety and toxicology studies, and a sharpened emphasis on translational research.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12600&type=smp

Which Primary Drivers Are Impacting The Preclinical Assets Market Growth?

The escalating imperative to mitigate clinical trial expenses is projected to stimulate the expansion of the preclinical asset market moving forward. Clinical trial costs denote the expenditures linked with conceiving, executing, and overseeing a clinical investigation to evaluate the safety, efficacy, and potential benefits of a new medical intervention, such as a pharmaceutical product, medical device, or therapeutic regimen. These investigations furnish vital information regarding the safety, effectiveness, and potential adverse reactions of preclinical assets, assisting in confirming their therapeutic promise in human subjects. For instance, in February 2023, according to Genetic Engineering and Biotechnology News, a US-based platform that delivers the most recent intelligence on genetic engineering and biotechnology, the expense of developing a new drug among the leading 20 global biopharma companies surged by 15%, increasing from $298 million in 2022 to approximately $2.3 billion in 2023, a sum that encompasses costs incurred during drug development through clinical trials. Therefore, the increasing urgency to control clinical trial costs is a significant factor propelling the growth of the preclinical assets market.

Which Segment Categories Are Included In The Preclinical Assets Market Segment Analysis?

The preclinical assets market covered in this report is segmented –

1) By Service: Bioanalysis And DMPK (Drug Metabolism And Pharmacokinetic) Studies, Toxicology Testing, Compound Management, Safety Pharmacology, Other Services

2) By Model Type: Patient Derived Organoid (PDO) Model, Patient Derived Xenograft Model

3) By End User: Biopharmaceutical Companies, Government Institutes, Other End-Users

Subsegments:

1) By Bioanalysis And DMPK (Drug Metabolism And Pharmacokinetic) Studies: Pharmacokinetics (PK) Studies, Pharmacodynamics (PD) Studies, Bioanalytical Method Development

2) By Toxicology Testing: Acute Toxicity Testing, Chronic Toxicity Testing, Genotoxicity Testing, Carcinogenicity Testing

3) By Compound Management: Compound Library Management, Sample Storage And Retrieval, High-Throughput Screening Support

4) By Safety Pharmacology: Cardiovascular Safety Assessments, Neurotoxicity Evaluations, Respiratory Safety Evaluations

5) By Other Services: Regulatory Support, Preclinical Study Design And Consulting, Custom Assay Development

Which Trends Are Shaping Growth In The Preclinical Assets Market?

Major companies operating within the preclinical assets market are concentrating on forming strategic alliances to accelerate the discovery and progression of innovative drug candidates. These partnerships facilitate the sharing of research expertise, provide access to novel targets, and advance early-stage preclinical assets. For instance, in July 2023, AbbVie, a US-based pharmaceutical company, and Calibr, an India-based research, drug development company, announced an expanded strategic collaboration to continue advancing several innovative preclinical and early-stage clinical assets. This partnership extends the prior collaboration between AbbVie and Scripps Research. Furthermore, Calibr will present AbbVie with a certain number of new discovery targets and preclinical assets of mutual interest for option considerations.

Who Are The Active Companies Shaping The Preclinical Assets Market?

Major companies operating in the preclinical assets market are Laboratory Corporation of America, IQVIA Inc., ICON PLC, Eurofins Scientific SE, PPD Inc., SGS SA, WuXi AppTec Co. Ltd., Intertrek Group PLC, Charles River Laboratories International Inc., Medpace Inc., Pharmaron Beijing Co. Ltd., Evotec SE, GenScript Biotech Corporation, Inotiv Inc., SRI International Inc., Shanghai Medicilon Inc., Biocytogen Pharmaceuticals Beijing Co. Ltd., AmplifyBio LLC, BioReliance Corporation, Pharmalegacy Laboratories Co. Ltd., ReproCELL Incorporated, InSphero AG, Crown Bioscience Inc., Comparative Biosciences Inc., TCG Lifesciences Pvt. Ltd., InVivo Biosystems, Pharmatest Services Ltd, Domainex Limited, Viroclinics Xplore

Get The Full Preclinical Assets Market Report:

https://www.thebusinessresearchcompany.com/report/preclinical-assets-global-market-report

Which Region Holds The Highest Market Share In The Preclinical Assets Market?

North America was the largest region in the preclinical assets market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the preclinical assets market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Preclinical Assets Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/preclinical-assets-global-market-report

Browse Through More Reports Similar to the Global Preclinical Assets Market 2026, By The Business Research Company

Psychiatrists Market

https://www.thebusinessresearchcompany.com/report/psychiatrists-market

Precision Diagnostics Market Report

https://www.thebusinessresearchcompany.com/report/precision-diagnostics-global-market-report

Digital Psychotherapeutics Market Report

https://www.thebusinessresearchcompany.com/report/digital-psychotherapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795